SINOVAC and Universitas Gadjah Mada Signed MoU to Deepen R&D Cooperation

Yogyakarta, April 21, 2026 - SINOVAC and Indonesia's Universitas Gadjah Mada, signed a memorandum of understanding in Yogyakarta on April 21, 2026 to deepen R&D cooperation.

Founded in 1949, Universitas Gadjah Mada is one of the oldest, largest, and most prestigious higher education institutions in Indonesia, with a well-established medical education and clinical trial system. The signing of this MOU of cooperation marks a key milestone for SINOVAC to initiate collaborative R&D with local research institutions and enterprises in Indonesia.

Ms. Yaling Hu, the Vice President of R&D, and Mr. Gang Zeng, the Senior Director of the Clinical R&D Center, represented SINOVAC for the signing ceremony. Ms. Hu expressed delight at the visit and the official signing of the cooperation MOU. She remarked that SINOVAC has maintained close cooperation with Indonesia since the COVID-19 pandemic, adding that the signing represents the first step of collaborative research between both sides and is expected to further broaden SINOVAC's collaboration with Indonesia's public health sector.

Speaking at the ceremony, Prof. dr. Ova Emilia, M.Med.Ed., Sp.OG(K), Ph.D., Rector of Universitas Gadjah Mada, noted that Indonesia has a population of over 288 million, and vaccines remain critical to the country's sustainable development amid potential future disease. She stressed the need to continuously deepen bilateral cooperation to drive vaccine development and elevate overall public healthcare services for the Indonesian people.

From left:

Ms. Yuliana Indriati, Director of R&D, PT Bio Farma (Persero)

Prof. dr. Ova Emilia, M.Med.Ed., Sp.OG(K), Ph.D., Rector of Universitas Gadjah Mada

Ms. Yaling Hu, Vice President of SINOVAC

Yuliana Indriati, Director of R&D at PT Bio Farma (Persero), welcomed the partnership between Sinovac and Universitas Gadjah Mada. She voiced optimism that the cooperation would promote joint vaccine R&D in Indonesia, foster local vaccine innovation, production and manufacturing capacity, and pledged full support and preparation for future collaboration.

This R&D cooperation further strengthens SINOVAC's partnership with Indonesia. Going forward, SINOVAC will continue collaborating with local academic and industry partners to advance vaccine innovation and support regional public health development.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis  vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.